Real-world outcomes in hereditary angioedema: first experience from the Icatibant Outcome Survey in the United Kingdom

Table 4 Time to treatment, time to resolution and duration of icatibant-treated HAE attacks

Endpoint	Patients with HAE type I or II
	UK (N = 73)			Non-UK (N = 579)			p value^b
	n ^a	Mean (SD)	Median (IQR)	n ^a	Mean (SD)	Median (IQR)	p value^b
Time from attack onset to treatment, h^c	222	2.9 (4.8)	0.8 (0.4, 3.0)	1120	3.9 (7.3)	1.3 (0.5, 4.0)	0.0632
Time to complete symptom resolution, h^d	222	10.5 (14.1)	6.0 (1.3, 14.0)	1120	11.8 (16.1)	5.8 (2.0, 14.1)	0.2774
Duration of attack, h^e	222	13.4 (15.4)	9.0 (2.5, 18.5)	1120	15.6 (18.9)	8.6 (4.0, 20.0)	0.1022

HAE hereditary angioedema, IQR interquartile range, n number of evaluable attacks, SD standard deviation
^aAttacks with complete data for time to treatment, time to complete resolution and attack duration, excluding attacks treated > 100 h after attack onset
^bMixed-model analysis of repeated measures comparing the UK versus non-UK IOS datasets
^cTime between the start of the attack and the first icatibant injection
^dTime between first injection of icatibant and complete resolution of symptoms
^eTime between start of attack and complete resolution of symptoms

ISSN: 1710-1492